{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:16:21Z","timestamp":1792757781362,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tjpad.2025.100447","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:03:12Z","timestamp":1767229392000},"page":"100447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tau in Alzheimer's disease: Shaping the future patient journey"],"prefix":"10.1016","volume":"13","author":[{"given":"Catherine J.","family":"Mummery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Chen","family":"Li-Hsian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian A.","family":"Lasagna-Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-3923","authenticated-orcid":false,"given":"Douglas W.","family":"Scharre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kyaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0001","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0002","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0004","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3233\/JAD-231259","article-title":"Assessing quality of life, economic burden, and independence across the Alzheimer's Disease continuum using patient-caregiver dyad surveys","volume":"99","author":"Tahami Monfared","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0006","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer Disease as a clinical-biological construct-an International Working Group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer's disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0012","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0013","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","article-title":"Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline","volume":"26","author":"Bucci","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100447_bib0014","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0015","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Brain Res Rev"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100447_bib0017","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.jmb.2017.03.018","article-title":"Interactions between tau and different conformations of tubulin: implications for tau function and mechanism","volume":"429","author":"Duan","year":"2017","journal-title":"J Mol Biol"},{"issue":"4\u20135","key":"10.1016\/j.tjpad.2025.100447_bib0018","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000095257","article-title":"Spectroscopic approaches to the conformation of tau protein in solution and in paired helical filaments","volume":"3","author":"von Bergen","year":"2006","journal-title":"Neurodegener Dis"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0019","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/pro.4257","article-title":"Three-repeat and four-repeat tau isoforms form different oligomers","volume":"31","author":"Shahpasand-Kroner","year":"2022","journal-title":"Protein Sci"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0021","article-title":"Alternative splicing in Alzheimer's disease","volume":"2","author":"Love","year":"2015","journal-title":"J Parkinsons Dis Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100447_bib0022","article-title":"Tau post-translational modifications: dynamic transformers of Tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13195-023-01321-7","article-title":"The therapeutic landscape of tauopathies: challenges and prospects","volume":"15","author":"Cummings","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100447_bib0024","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between a\u03b2 and Tau in the pathogenesis of Alzheimer's disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0025","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s00415-024-12314-3","article-title":"Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies","volume":"271","author":"Langerscheidt","year":"2024","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0026","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0959-4388(95)80058-1","article-title":"Biochemical and functional diversity of microtubule motors in the nervous system","volume":"5","author":"Brady","year":"1995","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1042\/bst0230544","article-title":"Roles for microtubules and kinesin in membrane traffic between the endoplasmic reticulum and the Golgi complex","volume":"23","author":"Lippincott-Schwartz","year":"1995","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0006-8993(92)91476-U","article-title":"Yen SH. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments","volume":"597","author":"Ksiezak-Reding","year":"1992","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0029","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/oxfordjournals.jbchem.a135662","article-title":"Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease","volume":"99","author":"Ihara","year":"1986","journal-title":"J Biochem"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1460-9568.2006.05226.x","article-title":"Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration","volume":"25","author":"Wang","year":"2007","journal-title":"Eur J Neurosci"},{"issue":"52","key":"10.1016\/j.tjpad.2025.100447_bib0031","doi-asserted-by":"crossref","first-page":"41340","DOI":"10.1074\/jbc.M006219200","article-title":"Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice","volume":"275","author":"Spittaels","year":"2000","journal-title":"J Biol Chem"},{"issue":"Pt 9","key":"10.1016\/j.tjpad.2025.100447_bib0032","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1242\/jcs.01018","article-title":"Grundke-Iqbal I. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport","volume":"117","author":"Tatebayashi","year":"2004","journal-title":"J Cell Sci"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100447_bib0033","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.neurobiolaging.2013.03.015","article-title":"Tau phosphorylation affects its axonal transport and degradation","volume":"34","author":"Rodr\u00edguez-Mart\u00edn","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.tjpad.2025.100447_bib0034","first-page":"2010","article-title":"Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease","author":"Jaworski","year":"2010","journal-title":"Int J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","article-title":"Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration","volume":"68","author":"Hoover","year":"2010","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100447_bib0036","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1523\/JNEUROSCI.4674-06.2007","article-title":"Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2\/par-1","volume":"27","author":"Thies","year":"2007","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0037","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1471-4159.2003.02287.x","article-title":"Pseudophosphorylation of tau protein alters its ability for self-aggregation","volume":"88","author":"Haase","year":"2004","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0038","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1111\/j.1460-9568.2007.05555.x","article-title":"Assembly of two distinct dimers and higher-order oligomers from full-length tau","volume":"25","author":"Sahara","year":"2007","journal-title":"Eur J Neurosci"},{"issue":"47","key":"10.1016\/j.tjpad.2025.100447_bib0039","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1021\/bi1016233","article-title":"Preparation and characterization of neurotoxic tau oligomers","volume":"49","author":"Lasagna-Reeves","year":"2010","journal-title":"Biochemistry"},{"issue":"26","key":"10.1016\/j.tjpad.2025.100447_bib0040","doi-asserted-by":"crossref","first-page":"23063","DOI":"10.1074\/jbc.M111.237974","article-title":"Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease","volume":"286","author":"Patterson","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0041","article-title":"Tau oligomers neurotoxicity","volume":"11","author":"Niewiadomska","year":"2021","journal-title":"Life (Basel)"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0042","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00401-023-02600-1","article-title":"Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau","volume":"146","author":"Mate De Gerando","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0043","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3233\/JAD-200716","article-title":"Functional integrity of synapses in the Central nervous system of cognitively intact individuals with high Alzheimer's Disease neuropathology is associated with absence of synaptic tau oligomers","volume":"78","author":"Singh","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100447_bib0044","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron","year":"2009","journal-title":"Mol Neurodegener"},{"issue":"1\u20132","key":"10.1016\/j.tjpad.2025.100447_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0891-0618(01)00096-5","article-title":"Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease","volume":"22","author":"Garc\u00eda-Sierra","year":"2001","journal-title":"J Chem Neuroanat"},{"issue":"29","key":"10.1016\/j.tjpad.2025.100447_bib0046","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0047","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0048","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0049","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0051","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41398-021-01602-5","article-title":"Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study","volume":"11","author":"Chen","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0052","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: rationale and clinical applications","volume":"20","author":"Therriault","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0053","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s43587-024-00626-y","article-title":"Spatiotemporal patterns of locus coeruleus integrity predict cortical tau and cognition","volume":"4","author":"Bueichek\u00fa","year":"2024","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0054","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100447_bib0056","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-981-32-9358-8_23","article-title":"Tau Prion-like propagation: state of the art and current challenges","volume":"1184","author":"Dujardin","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"14","key":"10.1016\/j.tjpad.2025.100447_bib0057","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","article-title":"Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain","volume":"111","author":"Colom-Cadena","year":"2023","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0058","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamaneurol.2024.2464","article-title":"Expanding the prion paradigm to include Alzheimer and Parkinson diseases","volume":"81","author":"Condello","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3 Pt 1","key":"10.1016\/j.tjpad.2025.100447_bib0059","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0060","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0061","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JAD-200808","article-title":"Relationships between cognition and neuropathological tau in Alzheimer's disease assessed by 18F flortaucipir PET","volume":"80","author":"Devous","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"524","key":"10.1016\/j.tjpad.2025.100447_bib0062","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci Transl Med"},{"issue":"48","key":"10.1016\/j.tjpad.2025.100447_bib0063","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd1327","article-title":"Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease","volume":"6","author":"Franzmeier","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.tjpad.2025.100447_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14250","article-title":"A framework for translating tauopathy therapeutics: drug discovery to clinical trials","author":"Feldman","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100447_bib0065","unstructured":"Citron M, Barton M, Bateman R, editors. Results from TOGETHER, a double-blind, placebo-controlled phase 2 study evaluating efficacy, safety and tolerability of bepranemab in prodromal\u2013mild Alzheimer\u2019s disease. 17th Clinical Trials on Alzheimer's Disease (CTAD) 2024 2024 29 October\u201301 November 2024; Madrid, Spain. The Journal of Prevention of Alzheimer\u2019s Disease - JPAD: The Journal of Prevention of Alzheimer\u2019s Disease - JPAD; 2025."},{"key":"10.1016\/j.tjpad.2025.100447_bib0066","unstructured":"ClinicalTrials.gov. A study of E2814 with concurrent Lecanemab treatment in participants with early Alzheimer's Disease ClinicalTrials.Gov2025 [updated 22\/01\/2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06602258."},{"key":"10.1016\/j.tjpad.2025.100447_bib0067","unstructured":"ClinicalTrials.gov. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU) 2024 [updated 03\/07\/2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01760005."},{"key":"10.1016\/j.tjpad.2025.100447_bib0068","unstructured":"ClinicalTrials.gov. A study to learn about the safety of BIIB080 injections and whether they can improve symptoms of participants with mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD dementia between 50 and 80 years of age (CELIA) 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05399888."},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0069","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer Disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100447_bib0071","series-title":"16th Clinical Trials on Alzheimer's Disease (CTAD) 2023","article-title":"Exploratory clinical outcomes from Biib080 (MAPT ASO) phase 1b multiple ascending dose and long-term extension study in mild Alzheimer\u2019S disease","author":"Ziogas","year":"2023"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100447_bib0072","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0073","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awz019","article-title":"Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers","volume":"142","author":"Gordon","year":"2019","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0074","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/alz.12356","article-title":"Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease","volume":"17","author":"Ossenkoppele","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100447_bib0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0076","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2967\/jnumed.120.254961","article-title":"Direct comparison of the tau PET tracers (18)F-Flortaucipir and (18)F-MK-6240 in Human subjects","volume":"63","author":"Gogola","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0077","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-021-05673-w","article-title":"International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer's disease","volume":"49","author":"Tian","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100447_bib0078","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer's disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat Aging"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0079","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","article-title":"Overview of tau PET molecular imaging","volume":"35","author":"Cassinelli Petersen","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0081","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging Human brain","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0082","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and Tau with cognition in preclinical Alzheimer disease: a longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100447_bib0083","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for Alzheimer's Disease: a 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tjpad.2025.100447_bib0084","series-title":"17th Clinical Trials on Alzheimer\u2019s Disease (CTAD)","article-title":"Effects of initial medial temporal lobe tauopathy and amyloid-beta on the timeline to Cataustrophe","year":"2024"},{"key":"10.1016\/j.tjpad.2025.100447_bib0085","series-title":"A Benefit\/Risk Update from Long-Term Efficacy, Safety and Biomarker Data. Alzheimer\u2019s Association International Conference","article-title":"Is there evidence for a continued benefit for long-term Lecanemab treatment?","year":"2024"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0086","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0087","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0088","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11011-022-00908-7","article-title":"Plasma phosphorylated-tau181 levels reflect white matter microstructural changes across Alzheimer's disease progression","volume":"37","author":"Nabizadeh","year":"2022","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0089","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification","volume":"12","author":"Barth\u00e9lemy","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100447_bib0090","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0091","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"13","key":"10.1016\/j.tjpad.2025.100447_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137307","article-title":"Tau as a biomarker of neurodegeneration","volume":"23","author":"Holper","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0093","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-023-00689-2","article-title":"Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology","volume":"19","author":"Therriault","year":"2024","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.tjpad.2025.100447_bib0094","series-title":"17th Clinical Trials on Alzheimer\u2019s Disease (CTAD)","article-title":"Timing of changes in Alzheimer\u2019S disease plasma biomarkers using amyloid and tau pet clocks","year":"2025"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100447_bib0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","article-title":"Disease staging of Alzheimer's disease using a CSF-based biomarker model","volume":"4","author":"Salvad\u00f3","year":"2024","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0096","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100447_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0098","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100447_bib0099","doi-asserted-by":"crossref","unstructured":"Horie K., Salvad\u00f3 G., Koppisetti R.K., Janelidze S., Barth\u00e9lemy N.R., He Y., et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 2025. 10.1038\/s41591-025-03617-7.","DOI":"10.1038\/s41591-025-03617-7"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100447_bib0100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","article-title":"Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease","volume":"31","author":"Islam","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100447_bib0101","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer's disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat Aging"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0107","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer's disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100447_bib0108","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","article-title":"Prevalence and clinical phenotype of quadruple misfolded proteins in older adults","volume":"77","author":"Karanth","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100447_bib0109","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(17)30284-3","article-title":"Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study","volume":"16","author":"Josephs","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100447_bib0110","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1038\/s41467-024-52299-1","article-title":"Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease","volume":"15","author":"Collij","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100447_bib0111","unstructured":"US Food and Drug Administration. LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous or subcutaneous use prescribing information (2025). https:\/\/www.leqembi.com\/en\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf?hash=5deab3d7-c731-44fc-8acc-2c49ee44822c&utm_source=digital&utm_medium=url_redirect&utm_campaign=yscb_wallet_card2025 [Available from: https:\/\/www.leqembi.com\/en\/-\/media\/Files\/Leqembi\/Prescribing-Information.pdf?hash=5deab3d7-c731-44fc-8acc-2c49ee44822c&utm_source=digital&utm_medium=url_redirect&utm_campaign=yscb_wallet_card."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100447_bib0112","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-Amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:26:02Z","timestamp":1776198362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2274580725003887"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100447","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tau in Alzheimer's disease: Shaping the future patient journey","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100447"}}